An extension trial to a phase I dose escalation study of LBQ707 (gimatecan) administered orally 5 consecutive days to Japanese patients with advanced solid tumor.

Trial Profile

An extension trial to a phase I dose escalation study of LBQ707 (gimatecan) administered orally 5 consecutive days to Japanese patients with advanced solid tumor.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2012

At a glance

  • Drugs Gimatecan (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jul 2010 Actual patient number (4) added as reported by ClinicalTrials.gov.
    • 02 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Jul 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top